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Terminal Sedation in Palliative Care
Abstract
Terminal sedation is an important procedure which aims at reducing patients suffering through the
reduction of their consciousness. Terminal sedation is used in cases of intractable symptoms in those who
are dying imminently. Sedation is distinct from euthanasia, although the distinction between these two
procedures may be blurred and may be confusing. Careful consideration, together with the patients, their
family and the multidisciplinary team, is of paramount importance.
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Take home messages
 Palliative sedation aims at relief of symptoms
not patients death.
 Morphine is not a sedative drug and should be
used only in combination with benzodiazepines.
 Palliative sedation is distinguishable from eutha-
nasia.
 Existential suffering not accompanied by intrac-
table physical symptoms is seen in most coun-
tries as insufficient ground to initiate terminal
sedation.
 Some patients may need higher doses of seda-
tives than the other.
 Terminal sedation has usually no influence of the
lengths of survival and the time of patients death
usually can not be predicted.
 Nurses have an important role in guaranteeing
dignity of sedated patients and their families.
 Sedation protocols and practice should be regu-
larly audited in each institution.
Introduction
When the end is near, in the last days of a pa-
tients life, some symptoms may be difficult to con-
trol. Drugs that worked before may appear to be
ineffective, either because of their poor absorption
from the gastrointestinal tract or subcutaneous in-
jection site or because of the rapid increase in the
intensity of symptoms. Pain is not the only symptom
that may prove to be uncontrollable at the end of
life. When everything else fails and suffering is un-
bearable, sedation may be the only solution.
Terminal sedation means the use of specific sed-
ative medications to relieve intolerable suffering from
refractory symptoms by the reduction of a patients
consciousness [1].
The concept of terminal sedation is not without
controversy [2]. As there are no (and will never be)
controlled data on the efficiency of this treatment,
there is an abundance of discussion by the experts
[37] and this is equally confusing both for profes-
sionals and the general public.
Instead of writing yet another guideline on
terminal sedation, we would like to clarify here
different aspects of the discussion around termi-
nal sedation, so the reader, equipped with new
knowledge and understanding, may better com-
prehend this debate or even take part in it. This
approach should also help readers to form their
own point of view. A number of practical com-
ments may help to provide better care at the
bedside.
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Which term to use?
Many people object to the term terminal seda-
tion. To some it suggests that the sedation has
something to do with termination and thus is indis-
tinguishable from euthanasia. Because of this, some
people have coined different names, such as pallia-
tive sedation, controlled sedation, total seda-
tion, sedation for the distress of the imminently
dying and many others [1]. New terms are invent-
ed daily but they only add to the confusion instead
of clarifying it. In fact, the term is not the most
important issue here. What is important is that it
applies to the imminently dying and those with in-
tractable or refractory symptoms. Terms such as
slow euthanasia should not be used.
When should terminal sedation be used?
In many patients, the imminence of dying can be
adequately recognized and the treatment can be
started upon this recognition. However, dying is a
complicated and somewhat unpredictable process
and health care workers, even with all their modern
diagnostic means, can be surprised by it. Death may
come earlier or later than expected, so the immi-
nence of approaching death is not always clear. In
practice, it is left to the discretion of the doctor.
Using exactly the same pharmacological means
in different phases of life in the absence of imminent
death could be seen as intention of life shortening
and is morally indistinguishable from euthanasia.
What are the refractory symptoms?
When symptoms can not be controlled and are
causing distress, patients may become unaware of
them once they have been sedated. This does not
mean that this treatment will or will not shorten a
patients life [8]. However, the concept of the re-
fractoriness of symptoms is also controversial [4].
Can the doctor ever say that everything has been
done to control symptoms? When doctors say this,
they mean that everything has been done but within
the limitations of time, place, knowledge, resources
and patients directives. If the patient and the fam-
ily do not want to be referred to a hospital or hos-
pice, the possibilities of treating the patient at home
may be limited. The knowledge and experience of
the doctor and the nurse at the bedside may also be
limited. Do doctors, therefore, always have an obli-
gation to look for more and better solutions or may
they give up and start sedation? No simple an-
swer exists to this question. The decision should be
proportional to the situation: both to what is avail-
able at the time and to what the doctor and nurse,
and preferably the whole multidisciplinary team, find
important and practicable.
Can psychological distress be seen
as a refractory symptom?
This is another point of controversy. Pain, nau-
sea, breathlessness and many other symptoms are
seen as physical symptoms and there are few doc-
tors who would refrain from sedation in the dying
when these symptoms are not relieved [4]. It is dif-
ferent with symptoms such as depression, anxiety
and paranoia, as well as delirium and existential
distress. Depression in particular is very difficult to
comprehend, as many depressed patients have sui-
cidal thoughts or even talk about euthanasia. Ap-
propriate and timely treatment of depression may
revert the wish to die. Doctors and nurses some-
times feel a high degree of pressure from patients
and families to proceed with sedation, while the
feeling is that not only should decisions be taken
without such insistence but that pressure may also
frequently provoke resistance. There is no doubt that
patients expressing psychological and existential
distress suffer sometimes even more than patients
with purely physical symptoms [9]. Psychological
distress usually accompanies the physical symptoms.
In one study in Japan, only 1% of sedations were
performed due to psychological distress alone [10].
In many if not most countries psychological and
existential suffering as stated above do not qualify
for sedation.
In what way is terminal sedation
different from euthanasia?
Terminal sedation is distinct from voluntary eu-
thanasia, at least in the definition. Euthanasia is
defined as the administration of drugs with the ex-
plicit intention of ending a patients life, at the pa-
tients explicit request [11]. Terminal sedation should
have no intentions (neither explicit nor implicit) of
ending a patients life, but rather the reduction of
distress due to refractory symptoms and uncontrolled
suffering. However, both procedures end with a pa-
tients death and, if there has been no family in-
volved in making decision, the doctor may be the
only one to judge whether this was a case of eutha-
nasia or terminal sedation. His intentions may be
clear from the records: for example, sedation might
have been started with a reasonable dose of benzo-
diazepines because of increasing and distressing pain
www.advpm.eu 49
Zbigniew Zylicz, Ma‡gorzata Krajnik, Terminal Sedation in Paliative Care
in dying patient (terminal sedation) or a patient who
had never received opioids was suddenly treated
with a very high bolus dose of morphine (euthana-
sia?). However, these matters are not always obvi-
ous and those doctors who want to conceal some-
thing will be very careful in leaving such obvious
traces behind. In some cases, therefore, terminal
sedation may be very similar to or indistinguishable
from euthanasia. As we think that terminal sedation
is legitimate in some cases of refractory symptoms
at the end of life and euthanasia is not, the banning
of both sedation and euthanasia, just because of
this lack of distinction, would cause a great deal of
suffering and would make dying more frightening
and less humane. To avoid this, doctors and nurses
should be in close contact with the patient (if possi-
ble), the family and their team. Ideally, the decision
about sedation should be taken by the multidisciplinary
team and should be recorded in detail, including the
doctors intentions. Only in this way can peers and the
public afford the doctor acclamation and trust.
In countries where euthanasia has been legal-
ized, this procedure is usually discussed earlier in
the course of the disease, when the patient is fully
conscious and can make an informed decision. The
very last days of a patients life make euthanasia
according to the law very difficult or even impossible
because patients may be confused and not compe-
tent to take decisions. Therefore, the last days of life,
in countries where euthanasia has been legalized,
are usually claimed to be the domain of terminal
sedation. In the Netherlands, cases of euthanasia have
decreased by one third in the last 5 years because of
a more widespread use of terminal sedation [12].
Does the principle of double effect
apply in cases of terminal sedation?
According to the principle of double effect, ef-
fects that would be morally wrong if caused inten-
tionally are permissible if foreseen but unintended
[13]. This principle criticised is rooted in a Catholic
morality and is accepted worldwide as an important
ethical standard. However, in the context of pallia-
tive care and terminal sedation, it is heavily criti-
cized [13], usually by proponents of a more liberal
approach to euthanasia and intentional death. Se-
dation may be seen as an adequate control of re-
fractory symptoms (good effect) and hastening death
as an unintended, unpredictable but permissible side
effect of this treatment (bad effect). Critics say that
this principle would be acceptable only if patients
received artificial hydration and feeding, which is
usually postponed at this time. In the eyes of the
authors, using artificial hydration and food may be
seen as disproportionate in the context of imminent
dying and may be more of a burden than a relief.
This discussion will probably never end.
Are there any hidden dangers
in the terminal sedation procedure?
The act of voluntary euthanasia is clear cut and
can be well defined [11]. The doctor gives lethal
drugs with the intention of ending a patients life
and the patient usually dies directly after the drugs
have been administered. Terminal sedation is less
easy to define using the same terms [1]. First of all,
the drugs administered are not intrinsically lethal.
Like many other drugs used in medicine, it is the
dose which perhaps causes the patient to die earli-
er, not the drug itself. The same drugs (benzodiaz-
epines) may be used in low and adequate doses to
control symptoms like fear and anxiety. Sedation is
not a single well-defined and clear-cut procedure
but a whole spectrum ranging from anxiolysis
through intermittent to moderate and deep seda-
tion, respiratory depression and death. Because of
this, sedation, more than other procedures, is prone
to abuse. In those countries where euthanasia is
allowed under certain conditions, doctors may abuse
terminal sedation as being less laborious, requiring
less paperwork and not needing to be reported with
the possibility of prosecution. In the Netherlands,
where the GPs are backed by consultants in Pallia-
tive Medicine, the abuse of terminal sedation in that
way happens more often on busy hospital wards,
but not at home [14, 15].
Which drugs are used in terminal
sedation?
Sedation is principally provided by benzodiaz-
epines. Soluble benzodiazepines, with a short half-
life like midazolam, are the drug of choice [1]. The
drugs used for terminal sedation are usually admin-
istered subcutaneously or intravenously using a sy-
ringe driver. However, the administration of benzo-
diazepines alone may result in a rapid development
of tolerance. This in turn may result in intolerable
suffering for the patient and the family when the
patient should, but is not able to sleep [16]. Usually,
adding low doses of morphine or diamorphine makes
the development of tolerance to midazolam less rapid
as well as avoids development of tolerance to mor-
phine [1719].
Opioids are not sedatives as such. Sedation by
opioids is usually transient and, at high doses, neu-
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roexcitation (stimulation of dynorphin A) may have
the opposite effect and even preclude sedation. Hos-
pital protocols where morphine is administered (usu-
ally intravenously) in increasing doses until a pa-
tients death [14] has little in common with terminal
sedation and may be correctly seen as an attempt at
euthanasia. In a minority of patients, liver enzymes
will be induced by the use of drugs like carbam-
azepine or smoking to the extent that the metabo-
lism of midazolam will be increased and plasma
levels greatly reduced [20, 21]. In these cases, barbi-
turates or propofol should be used [16]. However,
as barbiturates are used as a drug of choice in as-
sisted suicide [22], the use of them within the frame
of palliative sedation is not well accepted.
Apart from benzodiazepines and (dia)morphine,
levomepromazine is often used as an adjuvant drug in
terminal sedation [23]. It may have an intrinsic analge-
sic effect complementary to that of opioids; it may
have a sedative effect due to its H1 antihistamine ef-
fect; and it has an antipsychotic effect which is impor-
tant in the treatment of people with delirium and
agitation. Not unimportant is its powerful antiemetic
effect [24]. One of the drawbacks of levomepromazine
is a potent anticholinergic effect which usually neces-
sitates introduction of an indwelling bladder catheter.
Conscious patients may experience dry mouth.
A specific but rare situation occurs when a patient
responds paradoxically to benzodiazepines. This is usu-
ally due to a genetic mutation of the receptor protein.
The condition appears predominantly in children and
young adults [25] but occasionally can be seen in adults.
When benzodiazepines induce anxiety instead of con-
trolling it, flumazenil may be considered [26].
What dose can be seen as adequate
or proportional in terminal
sedation?
Due to the complexity of situations, there are no
fixed doses of sedatives that can be seen as ade-
quate or proportional. The effect of the drug, as
always, should be titrated against the desired ef-
fects. In some situations, as in distress due to acute
bleeding into the trachea, titration can be very rap-
id. However, these dramatic situations are very rare
in Palliative Care.
More commonly, there are hours or days in which
to titrate carefully the dose of sedative drugs. Ter-
minal sedation can be best initiated in the after-
noon or in the evening, after patients have seen
family members and they have seen the patient.
Such sedation resembles natural sleep and is less
distressing to the surrounding people (think about
the other patients in the bay). The initial dose of
sedative will depend on the previous use of benzo-
diazepines. Higher doses are needed to obtain seda-
tion in those patients who have been using high dose
night sedatives for a longer time. Preliminary evalua-
tion of subcutaneous midazolam/morphine adminis-
tration should be done after 46 hours, but one should
avoid changing the doses of infused drugs too early.
However if the patient is asleep and a-reflexive (deeply
sedated) 12 hours after administration, the dose is
probably too high and should be reduced. Contrary,
if the patient is still suffering (being awaken) 46
hours after administration, the dose may be too low
or liver enzymes have been induced by drugs like
carbamazepine and/or smoking and a different strat-
egy should be devised (see about propofol and barbi-
turates). If necessary, additional single doses of mi-
dazolam and morphine can be given subcutaneous-
ly. Sometimes failure of sedatives is due to inappro-
priate absorption from the subcutaneous tissue. In
such a case one can see the swelling around the
needle insertion. In case of absorption failure the
treatment should be continued intravenously.
Is there anything else the doctor
should think of considering with
terminal sedation?
Preparations for sedation are most important.
Are there enough ampoules available (during the
weekend?) even if the dose needs to be increased
later? Has the patient open his or her bowels recent-
ly or is the rectum full of impacted faeces? Is the
patients bladder empty? Sedated patients usually
need a bladder catheter, especially when they are
going to be sedated with levomepromazine. A full
rectum and/or bladder may produce powerful stim-
uli counteracting the sedating effects of drugs. It is
not infrequent that patients who are difficult to
sedate receive high doses of sedatives but do not
respond to them because of a full bladder. Empty-
ing the bladder may precipitate a patients deep
sedation and even sudden death, so try to insert the
catheter before bladder retention.
After the patient is sedated, doctors and nurses
should keep checking on the patient and continue
to inform the family of any change in condition.
How long it will take?
There are some signs which will say something
about the prognosis. While the patients are sedated
they do not take fluids and it is usual that the urine
volume decreases and the urine becomes more con-
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centrated. If patients suffer from considerable oede-
ma, they may mobilize the water from the oedema
first. The family should be informed about this. Clin-
ical experience suggests that overweight people com-
bust their fat to water and use this water to perfuse
the kidneys, this may result in the same effect as
with oedema.
Also clinical experience suggest that when urine
production is down to zero and the nurse can be
sure the catheter is not blocked, the prognosis is
short and there is a considerable likelihood of the
patients dying during the next 24 hours.
The role of the nurse
Nurses do have an important role in the care of
terminally ill and imminently dying people. Sedation
should be carefully prepared and discussed within
the team. Procedures and practice should be frequent-
ly audited. The reasons for sedation should be weight-
ed and well considered. Patients consciousness should
not be limited without an important reason. The care
should be taken that this last part of life is are peace-
ful and full of dignity. The patient should have time
and opportunity to say his good-buys to the family
and friends or do things which are important to him.
This can be achieved by appropriate timing of the
sedation. During the sedation, patients family should
be daily informed about patients condition and the
nurses should listen to the family members observa-
tions and doubt. If needed, the doctor should be
asked to elucidate appearing problems.
Conclusion
Terminal sedation is a legally acceptable proce-
dure which is used in many places in the World. Its
use is restricted to patients imminently dying and
with refractory symptoms. From them most impor-
tant are pain, breathlessness and delirium. Sedation
is not carried out with the intention of shortening a
patients life but is intended to decrease suffering.
Sedation is distinguishable from euthanasia. This area
is the subject of multiple and confusing discussions
and, unfortunately, the distinctions between seda-
tion and euthanasia are sometimes blurred and can
not be set in stone. Careful consideration with the
patient, family and the multidisciplinary team, as well
as the transparent documentation of such cases, will
help to illustrate the true intentions of the team.
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